All Hong Kong stocks quotes are at least 15 minutes delayed.
00241
ALI HEALTH
HKD
6.150-0.050
(-0.81%)
1D
AI Analysis for 00241
AI Analysis
High
6.170
Open
6.070
VWAP
6.07
Vol
53.21M
Mkt Cap
88.80B
Low
6.000
Amount
323.05M
EV/EBITDA(TTM)
46.95
Total Shares
16.18B
EV
11.53B
EV/OCF(TTM)
50.36
P/S(TTM)
2.77
Alibaba Health Information Technology Ltd is an investment holding company mainly engaged in the provision of Internet solutions for the medical and pharmaceutical industry, and is Alibaba Group’s healthcare flagship platform. The Company is mainly involved in the development of pharmaceutical and healthcare product and service sales business, the operation of pharmaceutical e-commerce platform and consumer healthcare services platform, the development of tracking and digital health business and Internet healthcare business using technologies such as cloud computing and big data.
Show More
News
4.5
01-30aastocks<Midday Update> HSI Falls by 498 Points; HSTI Declines by 105 Points; CSPC PHARMA Drops Over 12%; SHK PPT and HUABAO INTL Reach New Peaks
Market Performance: The Hang Seng Index (HSI) fell by 498 points (1.8%) to 27,469, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 1.8% and 2.1%, respectively.
Active Heavyweights: Major stocks like Xiaomi, Alibaba, and Tencent saw significant drops, with Xiaomi down 2.7%, Alibaba down 2.7%, and Tencent down 1.5%, alongside substantial short selling activity.
Notable Declines: CSPC Pharma and Zijin Mining faced sharp declines of 12.5% and 8.6%, respectively, with high short selling ratios indicating bearish market sentiment.
Gainers and New Highs: New Oriental and Huabao International were among the few gainers, with New Oriental up 3.6% and Huabao hitting a new high with a 6.2% increase.
4.5
01-28aastocksHSI Rises 598 Points at Midday, Reaching Over 4.5-Year High; Financials, Developers, and Commodities Flourishing
Market Performance: The HSI rose by 598 points (2.2%) to 27,725, with significant gains in the HSCEI and HSTECH, while total market turnover reached HKD196.327 billion.
Financial Stocks Surge: Major financial stocks like HSBC, BOC Hong Kong, and Standard Chartered saw increases of 2.1% to 2.9%, contributing to a positive trend in the financial sector.
Property and Resource Stocks Rally: Hong Kong developers and Chinese developers experienced substantial gains, with some stocks like China Jinmao and Greentown China rising by over 6%, while resource stocks also saw significant increases.
Tech and AI Stocks Growth: Tech stocks such as Tencent and JD-SW gained between 1.5% and 2.4%, while AI-related stocks like SenseTime and Unisound saw notable increases, with Unisound jumping by 38.2%.
4.5
01-21aastocksHSI Rises by 97 Points Driven by Demand for Chip, AI, and Robotics Stocks; HUA HONG SEMI Gains 5%
Market Performance: The Hong Kong stock market saw a rebound with the HSI rising 0.4% to 26,585, driven by the US-Europe dispute over Greenland and a total market turnover of HKD250.451 billion.
AI and Tech Stocks Surge: The launch of the new DeepSeek model, MODEL1, boosted AI and chip-related stocks, with notable gains from companies like SENSETIME-W and INSILICO, while some stocks like UNISOUND experienced declines.
Chinese Exports Growth: China's exports in December increased by 6.6% year-on-year, surpassing the previous value of 5.9% and exceeding forecasts of 3%.
Mixed Performance Among Major Tech Firms: BIDU-SW launched a new AI feature and saw a 3.3% stock increase, while other tech giants like TENCENT and JD-SW had modest gains, and NTES-S faced a significant decline of 3.7%.
4.5
01-21aastocks<Daily Summary> HSI Ends at 26,585, Gaining 97 Points; HSTI Finishes at 5,746, Up 62 Points; ANTA SPORTS Declines by More than 4%; BIDU-SW, MTR CORPORATION, POWER ASSETS, SINOPEC CORP, and CLP HOLDINGS Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) rose by 97 points (0.4%) to close at 26,585, while the Hang Seng Tech Index (HSTI) increased by 62 points (1.1%) to 5,746, with a total market turnover of $250.45 billion.
Active Heavyweights: Notable movements included Alibaba (BABA) up 2.2% to $163.2, Tencent (TENCENT) up 0.2% to $602.5, and Xiaomi (XIAOMI) down 0.2% to $35.42, with significant short selling activity across these stocks.
HSI & HSCEI Constituents: Anta Sports (ANTA) fell 4.2% to $79.1, while SMIC (SMIC) and Kuaishou (KUAISHOU) saw gains of 3.7% and 3.6%, respectively, indicating mixed performance among constituents.
HSMI & HSSI Constituents: Skyworth (SKYWORTH) surged 37.5% to $7.12, marking a new high, alongside other significant gainers like SF Intra-City (up 20.5%) and TCL Electronics (up 14.8%), reflecting strong upward trends in certain sectors.
4.5
01-21aastocksHSI Declines 39 Points at Noon; ANTA SPORTS Falls Over 5%; SMIC and HUA HONG SEMI Rise
Market Overview: The HSI closed down 39 points (0.2%) at 26,447, while the HSCEI fell 24 points (0.3%) to 9,070. The HSTECH saw a slight increase of 8 points (0.15%) to 5,691, with a total half-day turnover of HKD127.653 billion.
AI-Related Stocks Performance: Stocks like GDS-SW and UNISOUND experienced declines of 3.2% and 5.2%, respectively, while INSILICO and MINIMAX-WP surged by 5.5% and 6.6%.
Chip Sector Movements: SMIC, ASMPT, and HUA HONG SEMI saw gains of 3-4%, while INNOSCIENCE and BIREN TECH faced declines of 5.6% and 3.6%.
Tech Stocks Activity: BIDU-SW rose by 3.3% following a target price increase from Morgan Stanley and Citi, while other notable movements included a decline in LENOVO GROUP and a slight increase in KUAISHOU-W.
Money Flow
Over the past 66 trading days, overall net money flow is -99.42M, with retail investors contributing -8.50M and major investors adding -109.52M.
Net Buy $ Volume
Net Sell $ Volume
CLSA
CLSA
Outperform
maintain
2025-12-08
Reason
The analyst rating from CLSA for JD Health and Alibaba Health is maintained at "Outperform" due to a positive outlook for next year's growth in pharmaceutical sales and margin expansion. Despite projecting conservative guidance for 4Q25 based on a trade-in base effect, CLSA forecasts double-digit revenue growth for both companies next year, with JD Health expected to grow at a faster pace. The target price for JD Health is set at HK$71, while Alibaba Health's target price is trimmed to HK$6 to reflect a slower growth outlook.
CLSA
Outperform
Price Target
2025-12-08
maintain
The analyst rating from CLSA for JD Health and Alibaba Health is maintained at "Outperform" due to a positive outlook for next year's growth in pharmaceutical sales and margin expansion. Despite projecting conservative guidance for 4Q25 based on a trade-in base effect, CLSA forecasts double-digit revenue growth for both companies next year, with JD Health expected to grow at a faster pace. The target price for JD Health is set at HK$71, while Alibaba Health's target price is trimmed to HK$6 to reflect a slower growth outlook.
JPMorgan
JPMorgan
Neutral
maintain
$6.5
2025-12-03
Reason
The analyst rating for ALI HEALTH (00241.HK) is maintained at Neutral by JPMorgan due to a combination of factors. The company achieved strong revenue growth of 17% in 1HFY2026, primarily driven by the growth of originator drugs and structural changes in China's pharmaceutical market. However, there is uncertainty regarding the sustainability and incremental contribution of Taobao's instant retail, which could affect future sales growth. As a result, while the current momentum is positive, the broker advises caution and highlights the need to monitor fluctuations in instant retail subsidies and potential user churn. The target price is set at $6.5 based on a projected 2.5x EV/revenue multiple for FY2026.
JPMorgan
Neutral
Price Target
$6.5
2025-12-03
maintain
The analyst rating for ALI HEALTH (00241.HK) is maintained at Neutral by JPMorgan due to a combination of factors. The company achieved strong revenue growth of 17% in 1HFY2026, primarily driven by the growth of originator drugs and structural changes in China's pharmaceutical market. However, there is uncertainty regarding the sustainability and incremental contribution of Taobao's instant retail, which could affect future sales growth. As a result, while the current momentum is positive, the broker advises caution and highlights the need to monitor fluctuations in instant retail subsidies and potential user churn. The target price is set at $6.5 based on a projected 2.5x EV/revenue multiple for FY2026.
Goldman Sachs
Goldman Sachs
Neutral
maintain
2025-12-02
Reason
Goldman Sachs maintained a Neutral rating on ALI HEALTH (00241.HK) due to several key factors. The company is benefiting from structural industry tailwinds, such as the shift of original drugs from in-hospital channels and the growth of online drug sales. However, there is a noted divergence in revenue growth between ALI HEALTH and its competitor JD HEALTH, with ALI HEALTH lagging in establishing a comprehensive first-party (1P) business model, particularly in user awareness and supply chain capabilities. Despite this, Goldman Sachs sees potential upside in ALI HEALTH's results guidance for FY2026, driven by strong growth in its 1P platform sales and effective cost control. The target price was raised from $4.7 to $5.2, reflecting a 2027 PE ratio of 28x for its pharmacy and healthcare services projections.
Goldman Sachs
Neutral
Price Target
2025-12-02
maintain
Goldman Sachs maintained a Neutral rating on ALI HEALTH (00241.HK) due to several key factors. The company is benefiting from structural industry tailwinds, such as the shift of original drugs from in-hospital channels and the growth of online drug sales. However, there is a noted divergence in revenue growth between ALI HEALTH and its competitor JD HEALTH, with ALI HEALTH lagging in establishing a comprehensive first-party (1P) business model, particularly in user awareness and supply chain capabilities. Despite this, Goldman Sachs sees potential upside in ALI HEALTH's results guidance for FY2026, driven by strong growth in its 1P platform sales and effective cost control. The target price was raised from $4.7 to $5.2, reflecting a 2027 PE ratio of 28x for its pharmacy and healthcare services projections.
UBS
downgrade
2025-12-02
Reason
The analyst rating from UBS was downgraded due to a belief that the performance of ALI HEALTH was primarily driven by a structural shift from offline to online pharmaceutical supply, rather than a strategic pivot towards first-party platforms or first-party pharmaceutical sales. Despite the company's first-party platform sales growth surpassing forecasts, UBS maintains a cautious outlook, suggesting that leading peers may benefit more from this structural trend. Consequently, while the target price was raised, the Sell rating remained in place.
UBS
Price Target
2025-12-02
downgrade
The analyst rating from UBS was downgraded due to a belief that the performance of ALI HEALTH was primarily driven by a structural shift from offline to online pharmaceutical supply, rather than a strategic pivot towards first-party platforms or first-party pharmaceutical sales. Despite the company's first-party platform sales growth surpassing forecasts, UBS maintains a cautious outlook, suggesting that leading peers may benefit more from this structural trend. Consequently, while the target price was raised, the Sell rating remained in place.
CICC
CICC
upgrade
2025-11-28
Reason
The analyst rating for ALI HEALTH (00241.HK) is maintained at "Outperform" due to several key reasons:
1. Strong Financial Performance: The company's 1HFY26 results exceeded expectations, with a revenue increase of 17% year-over-year and a non-GAAP net profit growth of 38.7%. This indicates robust operational performance, particularly in the original prescription drug category.
2. Positive Forecast Adjustments: CICC raised its non-GAAP net profit forecasts for FY2026 and FY2027 by 16%, reflecting confidence in the company's ongoing profitability and growth potential.
3. Strategic Partnerships: The anticipated strengthening of strategic partnerships with upstream enterprises is expected to enhance contributions from areas beyond product sales, indicating a diversified growth strategy.
4. Sector Valuation Uplift: The recent increase in sector valuations has led to a 30% increase in the target price to $7.1, further supporting the positive outlook on the stock.
These factors collectively contribute to the analyst's favorable rating and outlook for ALI HEALTH.
CICC
Price Target
2025-11-28
upgrade
The analyst rating for ALI HEALTH (00241.HK) is maintained at "Outperform" due to several key reasons:
1. Strong Financial Performance: The company's 1HFY26 results exceeded expectations, with a revenue increase of 17% year-over-year and a non-GAAP net profit growth of 38.7%. This indicates robust operational performance, particularly in the original prescription drug category.
2. Positive Forecast Adjustments: CICC raised its non-GAAP net profit forecasts for FY2026 and FY2027 by 16%, reflecting confidence in the company's ongoing profitability and growth potential.
3. Strategic Partnerships: The anticipated strengthening of strategic partnerships with upstream enterprises is expected to enhance contributions from areas beyond product sales, indicating a diversified growth strategy.
4. Sector Valuation Uplift: The recent increase in sector valuations has led to a 30% increase in the target price to $7.1, further supporting the positive outlook on the stock.
These factors collectively contribute to the analyst's favorable rating and outlook for ALI HEALTH.
CLSA
Outperform
maintain
$6.5
2025-11-28
Reason
The analyst rating for ALI HEALTH was set to "Outperform" with a target price of HKD 6.5 due to several factors highlighted in the report. The company's 1HFY26 results slightly exceeded expectations, with both revenue and profit showing advancement driven by strong first-party sales, despite a miss in third-party platform performance. The adjusted net profit increased by 39% year-over-year, and the gross margin of 8.1% surpassed the broker's estimate of 7.7%. Additionally, ALI HEALTH maintained its FY2026 guidance, projecting revenue growth of 10-15% and profit growth of 20-30%, indicating confidence in future performance. The broker also anticipates sustained strong growth in sales of originator drugs, although there may be uncertainties in healthcare device sales as the effects of a trade-in program diminish.
CLSA
Outperform
Price Target
$6.5
2025-11-28
maintain
The analyst rating for ALI HEALTH was set to "Outperform" with a target price of HKD 6.5 due to several factors highlighted in the report. The company's 1HFY26 results slightly exceeded expectations, with both revenue and profit showing advancement driven by strong first-party sales, despite a miss in third-party platform performance. The adjusted net profit increased by 39% year-over-year, and the gross margin of 8.1% surpassed the broker's estimate of 7.7%. Additionally, ALI HEALTH maintained its FY2026 guidance, projecting revenue growth of 10-15% and profit growth of 20-30%, indicating confidence in future performance. The broker also anticipates sustained strong growth in sales of originator drugs, although there may be uncertainties in healthcare device sales as the effects of a trade-in program diminish.
Citi
Buy
maintain
$8.5
2025-11-27
Reason
The analyst rating for ALI HEALTH (00241.HK) is a "Buy / High Risk" based on several positive financial indicators. The company's interim revenue rose by 17% year-over-year, and its net profit of RMB1.266 billion exceeded expectations. Additionally, ALI HEALTH's adjusted net profit grew by 38.7% year-over-year, and its gross profit margin improved. The company also raised its full-year revenue growth guidance to 10-15% and its adjusted net profit growth guidance to 20-30%. Citi believes that the strong adjusted net profit growth will lead the market to focus on potential further increases in the company's results guidance. The target price set by Citi is HKD8.5.
Citi
Buy
Price Target
$8.5
2025-11-27
maintain
The analyst rating for ALI HEALTH (00241.HK) is a "Buy / High Risk" based on several positive financial indicators. The company's interim revenue rose by 17% year-over-year, and its net profit of RMB1.266 billion exceeded expectations. Additionally, ALI HEALTH's adjusted net profit grew by 38.7% year-over-year, and its gross profit margin improved. The company also raised its full-year revenue growth guidance to 10-15% and its adjusted net profit growth guidance to 20-30%. Citi believes that the strong adjusted net profit growth will lead the market to focus on potential further increases in the company's results guidance. The target price set by Citi is HKD8.5.
BofA Securities
BofA Securities
upgrade
2025-10-15
Reason
The analyst rating for ALI HEALTH (00241.HK) was upgraded to a Buy due to several key factors. BofA Securities predicted that the company will exceed consensus expectations for its results in the current fiscal year ending March 2026. They raised their revenue growth forecast by 4 percentage points to 14% and adjusted the net profit growth forecast by 10 percentage points to 30%. Additionally, the broker increased the adjusted net profit forecast for both the current and next fiscal year by 8% and raised the expected free cash flow compound annual growth rate (CAGR) from 42% to 45%.
The report highlighted robust sales during the "618" shopping event, increased investment by parent company Alibaba (BABA-W) in quick commerce, which boosted traffic on Alibaba Health's platforms, and benefits from higher advertising spending by merchants. These factors contributed to the positive outlook and the increase in the target price from HK$5.5 to HK$6.56.
BofA Securities
Price Target
2025-10-15
upgrade
The analyst rating for ALI HEALTH (00241.HK) was upgraded to a Buy due to several key factors. BofA Securities predicted that the company will exceed consensus expectations for its results in the current fiscal year ending March 2026. They raised their revenue growth forecast by 4 percentage points to 14% and adjusted the net profit growth forecast by 10 percentage points to 30%. Additionally, the broker increased the adjusted net profit forecast for both the current and next fiscal year by 8% and raised the expected free cash flow compound annual growth rate (CAGR) from 42% to 45%.
The report highlighted robust sales during the "618" shopping event, increased investment by parent company Alibaba (BABA-W) in quick commerce, which boosted traffic on Alibaba Health's platforms, and benefits from higher advertising spending by merchants. These factors contributed to the positive outlook and the increase in the target price from HK$5.5 to HK$6.56.
Macquarie
Underperform
to
Outperform
upgrade
2025-08-19
Reason
The analyst rating upgrade from Macquarie for ALI HEALTH (00241.HK) is based on several key factors:
1. Enhanced Profitability: Macquarie has raised its FY26-27 adjusted net profit forecasts for ALI HEALTH by 6% and 20%, respectively, indicating an expectation of improved financial performance due to market consolidation.
2. Structural Improvement in Online Healthcare: The report highlights that the online healthcare industry has seen structural improvements, with a shift in market share from offline to online channels, which is beneficial for ALI HEALTH.
3. Traffic Synergy from Alibaba: The integration of the 88VIP program by ALI HEALTH's parent company, Alibaba, is expected to provide additional traffic synergy benefits, further enhancing ALI HEALTH's market position.
These factors collectively led to the upgrade of the rating from Underperform to Outperform and an increase in the target price from HKD3.4 to HKD6.78.
Macquarie
Underperform
to
Outperform
Price Target
2025-08-19
upgrade
The analyst rating upgrade from Macquarie for ALI HEALTH (00241.HK) is based on several key factors:
1. Enhanced Profitability: Macquarie has raised its FY26-27 adjusted net profit forecasts for ALI HEALTH by 6% and 20%, respectively, indicating an expectation of improved financial performance due to market consolidation.
2. Structural Improvement in Online Healthcare: The report highlights that the online healthcare industry has seen structural improvements, with a shift in market share from offline to online channels, which is beneficial for ALI HEALTH.
3. Traffic Synergy from Alibaba: The integration of the 88VIP program by ALI HEALTH's parent company, Alibaba, is expected to provide additional traffic synergy benefits, further enhancing ALI HEALTH's market position.
These factors collectively led to the upgrade of the rating from Underperform to Outperform and an increase in the target price from HKD3.4 to HKD6.78.
Valuation Metrics
Forward PE
N/A
5Y Average PE
82.62
Current PE
29.77
Overvalued PE
402.90
Undervalued PE
-237.65
Forward EV/EBITDA
N/A
5Y Average EV/EBITDA
-172.89
Current EV/EBITDA
25.11
Overvalued EV/EBITDA
919.52
Undervalued EV/EBITDA
-1265.30
Forward PS
5Y Average PS
3.10
Current PS
2.03
Overvalued PS
5.85
Undervalued PS
0.36
Financials
AI Analysis
Annual
Quarterly
Trading Trends
Daily
Monthly
No data
Short Selling
People Also Watch